PDS Versus Prolene as Suture Material for Vaginal Sacrospinous Hysteropexy

Pelvic Organ Prolapse Clinical Trial

Official title:

PDS (Polydiaxonene Suture) Versus Prolene (Polypropylene Suture) as Suture Material for Vaginal Sacrospinous Hysteropexy - a Randomised Controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05964881
• Other study ID #: 2079
• Status: Recruiting
• Phase: N/A
• Start date: May 15, 2023
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: Medical University of Vienna
• Contact: Greta L Carllin, MD
• Phone: +43-1-40400-28220
• Email: greta.carlin[@]muv.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Introduction: Pelvic organ prolapse is a common gynecological disease, which about 50% of women develop in the course of their lives. There are many different options for surgical care, e.g. the uterus-preserving sacrospinal fixation (= sacrospinal hysteropexy = SSHP). This technique has been increasingly used in recent years. However, there is still no data on whether the fixation sutures should be performed with absorbable or non-absorbable threads. Internationally, both types of threads are routinely used and both types of threads are described in publications. So far, there is no comparative data on the effectiveness and subjective results. The aim of this study is to compare subjective symptom improvement Materials & Methods: This is a randomized, single-center superiority study. The sacrospinal fixation is performed according to a standardized method and two different types of threads (absorbable PDS sutures vs. non-absorbable Prolene sutures) are used for the fixation suture. Patients are randomized to either the absorbable PDS sutures group or the non-absorbable Prolene sutures group. The primary outcome of interest is the subjective symptom improvement 12 months after surgery (evaluated using the German version of the pelvic floor questionnaire). Secondary outcome variables are anatomical outcomes, condition-specific quality of life, and adverse events. 52 patients will be included in the study.

The results of the study will be published in peer-reviewed journals and the results will be presented at scientific meetings.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Anterior vaginal wall prolapse beyond the hymen (POP-Q-point Aa or Ba >0) with central defect

• Prolapse of the apical vaginal vault beyond the hymen (POP-Q point C >0) with central defect

• Symptoms of a vaginal bulge

• A primary reconstructive operation using sacrospinous hysteropexy is planned

Exclusion Criteria:

• Recurrent prolapse

• History of hysterectomy

• A primary reconstructive operation with mesh or obliterative surgery is planned

• An operation with hysterectomy is planned

• Known pelvic malignancy

• Known inflammatory disease

• Current systemic treatment with glucocorticoids or immunosuppressants

• The subject cannot or does not want to participate

Related Conditions & MeSH terms

• Pelvic Organ Prolapse
• Prolapse

Intervention

Procedure:
• sacrospinous hysteropexy
sacrospinous hysteropexy

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	German pelvic floor questionnaire (subjective symptom improvement)	subjective symptom improvement 12 months after surgery evaluated using the German version of the pelvic floor questionnaire, which consist of 4 domains and a total of 42 questions	12 months post surgery
Secondary	anatomical outcomes - POP-Q measurement	anatomical outcomes 12 months after surgery evaluated through POP-Q-system (standardised POP-Q scale ranging from 0-4; the higher the number the worse the prolapse)	12 months post surgery
Secondary	anatomical outcomes - ultrasound imaging	anatomical outcomes 12 months after surgery evaluated through ultrasound (transvaginal ultrasound to measure size of uterus, length of cervix, perineal ultrasound for 3d imaging of perineal muscles)	12 months post surgery
Secondary	German pelvic floor questionnaire (condition-specific quality of life)	condition-specific quality of life 12 months after surgery evaluated through validated german pelvic floor questionnaire (consisting of 4 domains and a total of 42 questions)	12 months post surgery
Secondary	Clavien Dindo Scale for adverse events	assessment of adverse events during the first 12 months after surgery evaluated according to the Clavien Dindo scale from 1-5, with 5 consisting death)	12 months post surgery
Secondary	Mini Nutritional Assessment	nutritional assessment 12 months after surgery (evaluated through Mini Nutritional Assessment (from 1-14 points: 12-14 points: normal nutrition, 8-11 points: at risk for malnutrition, 0-7 points: malnutrition)	12 months post surgery
Secondary	Visual Analog Scale	pain assessment 12 months after surgery evaluated through Visual Analog Scale (VAS: pictograms of facial expression at different levels ranging from free of pain, to worst possible pain)	12 months post surgery
Secondary	Numerical Rating Scale	pain assessment 12 months after surgery evaluated through Numeric Rating Scale (NRS: ranging from 0 (no pain) up to 10 (worst possible pain))	12 months post surgery
Secondary	Patient Impression of Improvement Index	patient impression of improvment assessment 12 months after surgery evaluated through Patient Global Impression of Improvement Index (PGI-I: ranging from 1: very much better to 4: no change)	12 months post surgery